Your browser is no longer supported. Please, upgrade your browser.
BHVN [NYSE]
Biohaven Pharmaceutical Holding Company Ltd.
Index- P/E- EPS (ttm)-13.04 Insider Own4.10% Shs Outstand60.08M Perf Week-4.87%
Market Cap4.47B Forward P/E- EPS next Y-6.58 Insider Trans1.08% Shs Float49.54M Perf Month0.73%
Income-766.80M PEG- EPS next Q-2.82 Inst Own91.30% Short Float10.80% Perf Quarter-18.01%
Sales63.60M P/S70.26 EPS this Y-19.70% Inst Trans-1.23% Short Ratio9.00 Perf Half Y-19.40%
Book/sh-6.50 P/B- EPS next Y38.30% ROA-126.40% Target Price102.18 Perf Year48.15%
Cash/sh5.68 P/C12.58 EPS next 5Y- ROE594.10% 52W Range42.74 - 100.77 Perf YTD-16.65%
Dividend- P/FCF- EPS past 5Y- ROI-198.10% 52W High-29.11% Beta1.02
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin72.20% 52W Low67.15% ATR3.09
Employees825 Current Ratio2.20 Sales Q/Q- Oper. Margin- RSI (14)44.80 Volatility4.68% 3.82%
OptionableYes Debt/Eq- EPS Q/Q-27.00% Profit Margin- Rel Volume1.22 Prev Close70.79
ShortableYes LT Debt/Eq- EarningsMay 10 BMO Payout- Avg Volume594.47K Price71.44
Recom1.70 SMA20-3.13% SMA50-3.70% SMA200-6.87% Volume728,066 Change0.92%
Mar-11-21Initiated UBS Buy $108
Dec-15-20Initiated H.C. Wainwright Buy $121
Apr-17-20Initiated Cowen Outperform $45
Feb-10-20Downgrade Oppenheimer Outperform → Perform
Feb-06-20Initiated Mizuho Buy
Nov-22-19Initiated Wedbush Outperform
Jun-25-19Reiterated Canaccord Genuity Buy $89 → $84
May-06-19Initiated Goldman Buy $92
Apr-09-19Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-04-19Reiterated Needham Buy $48 → $56
Jul-03-18Reiterated Needham Buy $36 → $48
Jul-02-18Reiterated Needham Buy $36 → $48
Apr-05-18Downgrade Barclays Overweight → Equal Weight $30 → $25
Feb-22-18Reiterated Canaccord Genuity Buy $30 → $39
Dec-15-17Initiated Canaccord Genuity Buy $30
Oct-03-17Reiterated Needham Buy $43 → $36
May-03-21 03:01PM  
Apr-30-21 01:34PM  
Apr-28-21 07:30AM  
Apr-13-21 07:30AM  
Apr-08-21 09:22AM  
Apr-07-21 04:10PM  
07:30AM  
Apr-06-21 07:30AM  
Apr-02-21 01:40AM  
Mar-29-21 03:01PM  
11:33AM  
07:30AM  
Mar-28-21 11:42AM  
Mar-23-21 03:56AM  
Mar-15-21 10:16PM  
04:32PM  
Mar-12-21 11:29AM  
Mar-11-21 11:20AM  
07:30AM  
Mar-10-21 06:22PM  
07:30AM  
Mar-04-21 03:57PM  
Mar-02-21 09:56AM  
Mar-01-21 04:00PM  
08:45AM  
07:59AM  
07:30AM  
06:30AM  
Feb-23-21 06:40PM  
Feb-22-21 07:30AM  
Feb-08-21 07:30AM  
Jan-25-21 07:30AM  
Jan-20-21 12:13PM  
Jan-19-21 04:12PM  
10:22AM  
Jan-18-21 10:10AM  
09:00AM  
Jan-07-21 07:30AM  
Jan-05-21 10:00AM  
09:08AM  
Jan-04-21 07:30AM  
Dec-30-20 08:49AM  
Dec-21-20 05:18PM  
Dec-16-20 07:30AM  
Dec-07-20 10:00AM  
Dec-03-20 12:33PM  
Dec-02-20 10:05AM  
Nov-30-20 08:00AM  
Nov-22-20 09:32PM  
Nov-19-20 09:51AM  
Nov-16-20 09:00AM  
07:30AM  
Nov-11-20 04:30PM  
Nov-10-20 10:39AM  
Nov-09-20 08:32AM  
08:00AM  
08:00AM  
06:30AM  
Nov-06-20 08:34AM  
Nov-02-20 09:15AM  
Oct-30-20 06:23PM  
Oct-29-20 12:51PM  
Oct-27-20 12:28PM  
Oct-15-20 11:41AM  
Oct-14-20 07:30AM  
Oct-04-20 09:19AM  
09:19AM  
Sep-28-20 07:00AM  
Sep-21-20 08:00AM  
Sep-10-20 07:00AM  
Sep-08-20 08:30AM  
04:34AM  
Sep-02-20 01:19PM  
Aug-10-20 11:55AM  
07:45AM  
Aug-07-20 09:47AM  
09:37AM  
Aug-06-20 01:42PM  
Aug-05-20 05:00PM  
Aug-03-20 08:00AM  
Jul-21-20 07:30AM  
Jul-16-20 07:52AM  
05:45AM  
Jul-15-20 11:41AM  
09:52AM  
07:30AM  
Jul-13-20 10:08AM  
Jul-08-20 07:30AM  
Jun-24-20 07:00AM  
Jun-16-20 07:00AM  
Jun-10-20 07:00AM  
Jun-08-20 02:13AM  
Jun-01-20 04:05PM  
May-28-20 06:46AM  
May-21-20 07:30AM  
May-18-20 07:30AM  
May-15-20 07:33AM  
May-07-20 04:10PM  
May-04-20 08:47AM  
Apr-27-20 07:30AM  
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHILDS JOHN WDirectorMar 17Buy76.0013,157999,9322,545,801Mar 17 05:13 PM
CHILDS JOHN WDirectorMar 02Buy85.1410,000851,3702,532,644Mar 03 09:22 PM
Coric VladChief Executive OfficerJan 06Option Exercise0.0012,500025,211Jan 08 08:48 PM
Conway CharlesChief Scientific OfficerJan 06Option Exercise0.003,750011,759Jan 08 08:48 PM
Engelhart JamesChief Financial OfficerJan 06Option Exercise0.003,750010,958Jan 08 08:48 PM
Gentile KimberlySVP, Clinical OperationsJan 06Option Exercise0.003,75009,438Jan 08 08:48 PM
Stock ElyseChief Medical OfficerJan 06Option Exercise0.001,25002,187Jan 08 08:49 PM
Stock ElyseChief Medical OfficerJan 06Option Exercise0.003,75007,438Jan 08 08:49 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseJan 06Option Exercise0.005,00009,251Jan 08 08:49 PM
Tilton JohnChief Commercial OfficerJan 06Option Exercise0.001,25003,151Jan 08 08:49 PM
Conway CharlesChief Scientific OfficerNov 25Option Exercise0.003,00008,639Nov 27 09:47 PM
Coric VladChief Executive OfficerNov 25Option Exercise0.0010,950016,935Nov 27 09:47 PM
Engelhart JamesChief Financial OfficerNov 25Option Exercise0.003,70008,222Nov 27 09:47 PM
Gentile KimberlySVP, Clinical OperationsNov 25Option Exercise0.003,75007,389Nov 27 09:48 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseNov 25Option Exercise0.003,00004,755Nov 27 09:48 PM
Stock ElyseChief Medical OfficerNov 25Option Exercise0.003,37505,219Nov 27 09:48 PM
Tilton JohnChief Commercial OfficerNov 25Option Exercise0.001,25002,020Nov 27 09:48 PM
CHILDS JOHN WDirectorNov 23Buy89.555,000447,7372,516,938Nov 23 08:40 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseNov 02Option Exercise50.7230,0001,521,60031,755Nov 04 08:31 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseNov 02Sale76.2230,0002,286,6761,755Nov 04 08:31 PM
Bailey GregoryDirectorOct 23Sale78.9110,403820,8662,545,658Oct 23 09:25 PM
Bailey GregoryDirectorOct 22Sale79.4724,5661,952,3522,556,061Oct 23 09:25 PM
Bailey GregoryDirectorOct 19Sale78.984,554359,6552,580,627Oct 21 09:24 PM
Bailey GregoryDirectorOct 16Sale78.883,748295,6382,585,181Oct 21 09:24 PM
Bailey GregoryDirectorOct 12Sale78.876,729530,7402,588,929Oct 14 09:31 PM
Gentile KimberlySVP, Clinical OperationsOct 08Option Exercise9.2923,500218,31527,139Oct 09 06:42 PM
Gentile KimberlySVP, Clinical OperationsOct 08Sale76.3423,5001,794,0823,639Oct 09 06:42 PM
CHILDS JOHN WDirectorSep 21Buy59.253,322196,8282,511,938Sep 22 09:51 PM
CHILDS JOHN WDirectorSep 11Buy59.006,678393,9842,508,616Sep 14 08:49 PM
CHILDS JOHN WDirectorAug 11Buy61.5425,0001,538,4852,501,938Aug 12 06:25 PM
Berman RobertSpecial Projects & Med OvrsghtJul 08Option Exercise0.6158,40435,62658,745Jul 10 09:15 PM
Bailey GregoryDirectorJul 08Sale75.2250,0003,760,7652,595,658Jul 10 09:16 PM
Berman RobertSpecial Projects & Med OvrsghtJul 08Sale75.2558,4044,394,890341Jul 10 09:15 PM
Bailey GregoryDirectorJun 24Sale69.863,995279,0902,645,658Jun 25 09:49 PM
Berman RobertSpecial Projects & Med OvrsghtJun 23Option Exercise0.614,2962,6214,637Jun 25 09:49 PM
Berman RobertSpecial Projects & Med OvrsghtJun 23Sale75.054,296322,431341Jun 25 09:49 PM
Bailey GregoryDirectorJun 23Sale74.15101,6437,536,4322,649,653Jun 25 09:49 PM
Bailey GregoryDirectorJun 22Sale73.2480,3315,883,1752,751,296Jun 22 09:58 PM
Berman RobertSpecial Projects & Med OvrsghtJun 19Option Exercise0.619866011,327Jun 22 09:57 PM
Bailey GregoryDirectorJun 19Sale71.22164,03111,682,7572,831,627Jun 22 09:58 PM
Berman RobertSpecial Projects & Med OvrsghtJun 19Sale75.0798674,016341Jun 22 09:57 PM
Berman RobertSpecial Projects & Med OvrsghtJun 18Option Exercise2.6461,314162,15261,655Jun 22 09:57 PM
Berman RobertSpecial Projects & Med OvrsghtJun 18Sale75.2761,3144,615,290341Jun 22 09:57 PM
Gentile KimberlySVP, Clinical OperationsJun 17Option Exercise5.6024,000134,40027,639Jun 17 09:55 PM
Gentile KimberlySVP, Clinical OperationsJun 17Option Exercise5.604002,2404,039Jun 18 09:51 PM
Gentile KimberlySVP, Clinical OperationsJun 17Sale70.2040028,0813,639Jun 18 09:51 PM
Gentile KimberlySVP, Clinical OperationsJun 17Sale70.2024,0001,684,8703,639Jun 17 09:55 PM
Doogan DeclanDirectorJun 16Sale68.2260,0004,092,959626,002Jun 17 09:55 PM
Doogan DeclanDirectorJun 15Sale66.7380,0005,338,791686,002Jun 17 09:55 PM
Stock ElyseChief Medical OfficerJun 12Option Exercise25.9036,966957,51138,810Jun 12 09:51 PM
Doogan DeclanDirectorJun 12Sale64.7380,0005,178,453766,002Jun 12 08:09 PM
Stock ElyseChief Medical OfficerJun 12Sale64.8336,9662,396,5021,844Jun 12 09:51 PM
Engelhart JamesChief Financial OfficerJun 11Option Exercise9.2919,772183,68224,294Jun 12 05:19 PM
Doogan DeclanDirectorJun 11Sale63.4180,0005,072,600846,002Jun 12 08:09 PM
Engelhart JamesChief Financial OfficerJun 11Sale63.4319,7721,254,0574,522Jun 12 05:19 PM
Tilton JohnChief Commercial OfficerJun 10Option Exercise9.2952,000483,08052,770Jun 12 05:19 PM
Engelhart JamesChief Financial OfficerJun 10Option Exercise4.7653,953257,07358,475Jun 12 05:19 PM
Engelhart JamesChief Financial OfficerJun 10Sale67.0753,9533,618,5454,522Jun 12 05:19 PM
Tilton JohnChief Commercial OfficerJun 10Sale67.3852,0003,504,001770Jun 12 05:19 PM
Gentile KimberlySVP, Clinical OperationsJun 08Option Exercise5.606003,3604,239Jun 10 09:24 PM
Gentile KimberlySVP, Clinical OperationsJun 08Sale70.0560042,0273,639Jun 10 09:24 PM
Bailey GregoryDirectorJun 05Option Exercise4.69438,2002,053,9383,025,801Jun 08 05:15 PM